Meeting
2021 ASCO Annual Meeting
Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma.
Authors
Ainhoa Madariaga
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Ainhoa Madariaga , Swati Garg , Nairi Tchrakian , Neesha C. Dhani , Waldo Jimenez , Stephen Welch , Helen Mackay , Josee-Lyne Ethier , Lucy Gilbert , Angela Rodriguez , Lucy Chan , Valerie Bowering , Blaise Clarke , Tracy Stockley , Xuan Li , Lisa Wang , Smitha Udagani , Amit M. Oza , Stephanie Lheureux
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Clinical Trial Registration Number
NCT03016338
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 5574)
DOI
10.1200/JCO.2021.39.15_suppl.5574
Abstract #
5574
Poster Bd #
Online Only
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients.
First Author: Olga Zamulko
Poster
2022 ASCO Annual Meeting
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
First Author: JUNG-YUN LEE
Poster
2022 ASCO Annual Meeting
A phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma.
First Author: Vidhya Karivedu
Poster
2019 ASCO Annual Meeting
Elucidation of PARP inhibitor activity in BRCAwt recurrent ovarian cancer by hrr mutational gene profile analysis.
First Author: Mansoor Raza Mirza